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• Despite some conflicting results, the mentioned polymorphisms in MTHFR, SLCO1B1, SLC19A1 and 
ABCB1 genes are considered to have an important potential for developing personalized medicine. 
However,  further evaluation of the genetic polymorphisms is needed in order to definitely  stablish 
their effect on MTX treatment in ALL patients. 
• MTX plasma concentration is though to be associated with an increase of toxicity. 
• Although positive associations between genetic polymorphisms and response to MTX treatment 
have been reported, we are still far from being able to apply pharmacogenetic tests in routine 
clinical practice. 
 
Acute Lymphoblastic Leukemia (ALL) is a hematologic malignancy that 
affects blood cells and originates in the bone marrow, where 
haematopoiesis occurs. ALL is the most common form of childhood 
leukemia as well as the most common diagnosed childhood cancer 
(25-30%).   
This form of blood cancer is characterised by an overproduction of 
immature white blood cells, called lymphoblasts. Due to their 
immaturity, these malignant cells are unable to function properly to 
prevent and fight infection. 
Tumor cells are the result of a multi-step process of carcinogenesis and 
are characterized by being carriers of genetic alterations. This means 
that, together with their continuing proliferation, they accumulate in 
the bone marrow and arrest the production of healthy cells.  
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Aims to determine how the genetic makeup of 
each individual influences the response to drugs. 
Polymorphisms can modulate the response to a 
drug or therapy 
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Figure 2. Metabolic Pathway of MTX. (Adaptation of Schmeling H. et al., 
2014)  
 
Methotrexate (MTX) belongs to the class of 
chemotherapy drugs called antimetabolites. In 
particular, they have the ability to join the cellular 
metabolism causing the cells to lose their ability to 
divide. Specifically, MTX is a folic acid antagonist. 
Methotrexate 
Figure 1. Folic acid and methotrexate only differ in an 
amino and a methyl-group 
IDENTIFIED PROBLEMS 
The aim of the present poster is to review  the actual state of knowledge of pharmacogenetics and childhood Acute Lymphoblastic Leukemia focused on treatment 
with Metrotrexate 
 
• Cytogenetic Location: 21q22.3 
• Main transporter of MTX into cells 
 
 
 
 
 
• Polymorphisms: G80A 
 
 
SLC19A1 
Figure 5. Kaplan-Meier analysis of SLC19A1 
and outcome. (Gregers J. 2012) 
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Majority of studies had been developed with relatively small number of patients. 
 
It has not been established a unified protocol for ALL treatment with MTX and  
research on the effect of each genetic variant.  
 
Lack of consistency in quantifying the association between  genotype and  MTX 
response and toxicity. 
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• Cytogenetic Location: 7q21.12 
• P-Glycoprotein            functional barrier 
 
 
 
 
 
• Polymorphisms: C3435T and G1199A 
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Figure 3. P-Glycoprotein 
structure.  (Das A. et al. 
2011) 
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Leucovorin acts protecting healthy cells from MTX effects while allowing the entry of MTX 
into tumor cells to kill them. 
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• Cytogenetic Location: 1p36.3 
 
 
 
 
 
• Polymorphisms: 677C>T 
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Figure 4. Kaplan-Meier analysis of  disease-free 
survival and C677>T genotype [1 (CC+CT) versus 2 
(TT)]. (D’Angelo V. et al., 2011) 
 
• Cytogenetic Location: 12p 
 
 
 
 
 
• Polymorphisms: rs4149081, rs11045879 
and  rs4149056 
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